GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » RadNet Inc (NAS:RDNT) » Definitions » Peter Lynch Fair Value

RadNet (RadNet) Peter Lynch Fair Value : $1.78 (As of Apr. 28, 2024)


View and export this data going back to 1997. Start your Free Trial

What is RadNet Peter Lynch Fair Value?

Peter Lynch Fair Value applies to growing companies. The ideal range for the growth rate is between 10 - 20% a year. Peter Lynch thinks that the fair P/E value for a growth company equals its growth rate, that is PEG = 1. The earnings here is trailing twelve month (TTM) earnings. For non-bank companies, the growth rate we use is the average growth rate for EBITDA per share over the past 5 years. For Banks, the growth rate we use is the average growth rate for Book Value per share over the past 5 years. If 5-Year Growth Rate is greater than 25% a year, we use 25. If 5-Year Growth Rate is smaller than 5% a year, we do not calculate Peter Lynch Fair Value.

Here, as of today, RadNet's PEG is 1. RadNet's 5-Year TTM EBITDA Growth Rate is 5.75. RadNet's EPS without NRI for the trailing twelve months (TTM) ended in Dec. 2023 was $0.31. Therefore, the Peter Lynch Fair Value for today is $1.78.

As of today (2024-04-28), RadNet's share price is $48.40. RadNet's Peter Lynch fair value is $1.78. Therefore, RadNet's Price to Peter Lynch Fair Value Ratio for today is 27.15.


The historical rank and industry rank for RadNet's Peter Lynch Fair Value or its related term are showing as below:

RDNT' s Price-to-Peter-Lynch-Fair-Value Range Over the Past 10 Years
Min: 3.36   Med: 5.36   Max: 27.19
Current: 27.19


During the past 13 years, the highest Price to Peter Lynch Fair Value Ratio of RadNet was 27.19. The lowest was 3.36. And the median was 5.36.


RDNT's Price-to-Peter-Lynch-Fair-Value is ranked worse than
96% of 50 companies
in the Medical Diagnostics & Research industry
Industry Median: 1.625 vs RDNT: 27.19

Note: Please don't confuse Peter Lynch Fair Value with the value reached in Peter Lynch Chart.


RadNet Peter Lynch Fair Value Historical Data

The historical data trend for RadNet's Peter Lynch Fair Value can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

RadNet Peter Lynch Fair Value Chart

RadNet Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Peter Lynch Fair Value
Get a 7-Day Free Trial Premium Member Only Premium Member Only 3.79 - 8.95 - 1.78

RadNet Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Peter Lynch Fair Value Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - 2.76 1.78

Competitive Comparison of RadNet's Peter Lynch Fair Value

For the Diagnostics & Research subindustry, RadNet's Price-to-Peter-Lynch-Fair-Value, along with its competitors' market caps and Price-to-Peter-Lynch-Fair-Value data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


RadNet's Price-to-Peter-Lynch-Fair-Value Distribution in the Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, RadNet's Price-to-Peter-Lynch-Fair-Value distribution charts can be found below:

* The bar in red indicates where RadNet's Price-to-Peter-Lynch-Fair-Value falls into.



RadNet Peter Lynch Fair Value Calculation

RadNet's Peter Lynch Fair Value for today is calculated as

Peter Lynch Fair Value=PEG Ratio*5-Year TTM EBITDA Growth Rate***EPS without NRI (TTM)
=1* 5.75 *0.31
=1.78

RadNet's EPS without NRI for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.31.


* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

** Please be aware that the 5-Year TTM EBITDA Growth Rate is calculated based on TTM data over the last 5 years. For quarterly reported companies, the TTM data adds up the quarterly data reported by the company within the most recent 12 months. For companies that report semi-annually, annually, or do not have enough quarterly data, GuruFocus uses the annual data as the TTM data.

If 5-Year Earnings Growth Rate is greater than 25% a year, we use 25.

If 5-Year Earnings Growth Rate is smaller than 5% a year, we do not calculate Peter Lynch Fair Value.

Please note that we use the 5-year average growth rate of EBITDA per share as the growth rate for non-bank companies, as EBITDA growth is subject to less manipulations than net earnings per share. For banks, we use the 5-year average growth rate of Book Value per share as the growth rate. The reason is that EBITDA is not applicable to Banks and Book value is a relative important measurement for Banks. In the calculation, PEG=1 because Peter Lynch thinks that the fair P/E ratio of the growth stock is equal to its earnings growth rate.


RadNet  (NAS:RDNT) Peter Lynch Fair Value Explanation

Peter Lynch Fair Value applies to growing companies. The ideal range for the growth rate is between 10 - 20% a year.

Peter Lynch thinks that the fair P/E value for a growth company equals its growth rate, that is PEG = 1. The earnings here is trailing twelve month (TTM) earnings. For non-bank companies, the growth rate we use is the average growth rate for EBITDA per share over the past 5 years. For Banks, the growth rate we use is the average growth rate for Book Value per share over the past 5 years.

Please don't confuse Peter Lynch Fair Value with the value reached in Peter Lynch Chart. In Peter Lynch chart, a fixed P/E ratio of 15 is used to draw the Earnings Line. Therefore the value reached has a P/E ratio of 15. But in Peter Lynch Fair Value calculation, P/E equals to the growth rate of EBITDA per share over the past 5 years, which is 5.75 instead of 15 in this case.

RadNet's Price to Peter Lynch Fair Value Ratio for today is calculated as

Price to Peter Lynch Fair Value=Share Price/Peter Lynch Fair Value
=48.40/1.78
=27.15

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


RadNet Peter Lynch Fair Value Related Terms

Thank you for viewing the detailed overview of RadNet's Peter Lynch Fair Value provided by GuruFocus.com. Please click on the following links to see related term pages.


RadNet (RadNet) Business Description

Traded in Other Exchanges
Address
1510 Cotner Avenue, Los Angeles, CA, USA, 90025
RadNet Inc is a national provider of diagnostic imaging services that operates in two business segments; Imaging Center segment provides physicians with imaging capabilities to facilitate the diagnosis and treatment of diseases and disorders. Services include magnetic resonance imaging (MRI), computed tomography (CT), positron emission tomography (PET), nuclear medicine, mammography, ultrasound, diagnostic radiology (X-ray), fluoroscopy and other related procedures, and Artificial Intelligence segment develops and deploys clinical applications to enhance interpretation of medical images and improve patient outcomes with an emphasis on brain, breast, prostate, and pulmonary diagnostics. The company derives a majority of its revenue from the Imaging center segment.
Executives
Michael N Murdock officer: Executive Vice President 3600 JP MORGAN CHASE TOWER, 2200 ROSS AVENUE, DALLAS TX 752012776
Christine Nayoma Gordon director 3081 PANAMA AVE., CARMICHAEL CA 95608
Gregory Sorensen director, officer: EVP Chief Science Officer C/O DFB HEALTHCARE ACQUISITIONS CORP, 780 THIRD AVENUE, NEW YORK NY 10017
Norman R Hames director, officer: Vice President
Stephen M Forthuber officer: Executive Vice President 3600 JP MORGAN CHASE TOWER, 2200 ROSS AVENUE, DALLAS TX 75201-2776
Ruth Louisa Villigerwilson director, officer: Senior Vice President 3700 WALNUT AVENUE, LONG BEACH CA 90801
David L Swartz director 1510 COTNER AVENUE, LOS ANGELES CA 90025
Gregory E. Spurlock director 4116 E. NORTHRIDGE CIRCLE, MESA AZ 85215-9807
John V Crues director 1510 COTNER AVE, LOS ANGELES CA 90025
Lawrence L Levitt director 2934 1/2 BEVERLY GLEN CIRCLE #325, LOS ANGELES CA 90077
Ranjan Jayanathan officer: Chief Information Officer 13388 HUNT RIDGE ROAD, ELLICOTT CITY MD 21042
Laura Pastre Jacobs director 10154 BRIDLEVALE DRIVE, LOS ANGELES CA 90064
Karen B. Kaplan Survivor's Trust other: Indirect owner 10776 WILSHIRE BLVD/, LOS ANGELES CA 90024-6447
David Jeffrey Katz officer: EVP and General Counsel 1510 COTNER AVE, LOS ANGELES CA 90025
Sherman Michael L Md director

RadNet (RadNet) Headlines